Author

M. Arias

Observed name: Mª Efigenia Arias

Institutions: Universidade de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago

Observed institutions: Universidade de Santiago de Compostela, Bristol-Myers Squibb (United States), Instituto de Investigación Sanitaria de Santiago, Celgene (United States), Universidad Autónoma de Madrid

OpenAlex ID: A5113077892

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

2020 · V. Moreno, J.M. Sepulveda, et al. · Annals of Oncology · 68

Vasoconstrictor effects of serotonin in the isolated superior mesenteric artery of cat

1981 · J. Marín, M. Arias, et al. · General Pharmacology The Vascular System · 5

18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study

2020 · A. Hollebecque, J.S. de Bono, et al. · Annals of Oncology · 4

7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

2021 · A. Hollebecque, J.S. de Bono, et al. · Annals of Oncology · 2

POU1F1 induces cancer stem cell-like traits in breast cancer cells by IL-6/JAK2/STAT3 activation and enrichment of ALDH

2026 · Leandro Avila, Samuel Seoane, et al. · npj Breast Cancer · 1

Extracorporeal dialysis: techniques and adequacy

2012 · C. Donadio, A. Kanaki, et al. · Nephrology Dialysis Transplantation · 1

A phase 1B/2A randomised, placebo-controlled clinical trial with SNF472 in haemodialysis patients

2016 · C. Salcedo, J. Perelló, et al.

Works count: 8

Citation count: 82

H-index: 3

I10-index: 1